OC
CLRB icon

Oppenheimer & Co’s Cellectar Biosciences CLRB Stock Holding History

Oppenheimer & Co’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-417
Closed -$3.94K – 1612
2025
Q1 		$3.94K Hold
417
– – ﹤0.01% 1564
2024
Q4 		$3.74K Hold
417
– – ﹤0.01% 1548
2024
Q3 		$26.8K Buy
+417
New +$27.5K ﹤0.01% 1494

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Oppenheimer & Co's CLRB Position: Q2 2025 in Review

Oppenheimer & Co sold out of Cellectar Biosciences (CLRB) in Q2 2025, closing a stake of 417 shares — an estimated $3.94K sold.

Oppenheimer & Co first reported a position in CLRB in Q3 2024 and held it in 3 quarters. The position peaked at $26.8K in Q3 2024. 19 funds tracked by Wall St. Rank hold CLRB as of Q2 2025.

  • Oppenheimer & Co reported no remaining Cellectar Biosciences position as of Q2 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 417 Cellectar Biosciences shares in Q2 2025, an estimated $3.94K.
  • Oppenheimer & Co first reported a position in Cellectar Biosciences in Q3 2024 and held it in 3 quarters.
  • Oppenheimer & Co's Cellectar Biosciences position peaked at $26.8K in Q3 2024.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2025.

Based on Oppenheimer & Co's 13F filing for Q2 2025, filed 31 Jul 2025.